ATOS Stock Analysis: Buy, Sell, or Hold?
ATOS - Atossa Therapeutics, Inc. Common Stock
$2.31
-0.09 (-3.75%)
▼
5d:
-7.23%
30d:
-10.64%
90d:
-56.5%
HOLD
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
27d
Get Alerted When ATOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ATOS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ATOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ATOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ATOS is currently trading at $2.31, which is considered fair relative to its 30-day fair value range of $1.65 to $3.37.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $1.92, while resistance sits at $2.60. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: ATOS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+816.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $1.92, while resistance sits at $2.60. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: ATOS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+816.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.65 -
$3.37
Company Quality Score
53/100
(HOLD)
Options IV Signal
19th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
85.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 19th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 816.7% below Wall St target ($22.00)
- CAUTION: Recommendation downgraded due to -7.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.65 -
$3.37
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.51
(22.1%)
Support & Resistance Levels
Support Level
$1.92
Resistance Level
$2.60
Current Trend
Strong Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.55
Wall Street Target
$22.00
(+816.7%)
Share & Embed Analysis
Last updated: July 14, 2026 3:43 PM ET
Data refreshes hourly during market hours. Next update: 4:43 PM
Data refreshes hourly during market hours. Next update: 4:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
